We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Common Contracts

6 similar Underwriting Agreement contracts by Synlogic, Inc., Altimmune, Inc., Celularity Inc, others

•] Shares of Common Stock (or Pre-Funded Warrants to Purchase Shares of Common Stock in Lieu Thereof) Warrants to Purchase [•] Shares of Common Stock SYNLOGIC, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • September 29th, 2023 • Synlogic, Inc. • Pharmaceutical preparations • New York

Synlogic, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Chardan Capital Markets, LLC, as underwriter (“Chardan” or the “Underwriter”) (i) an aggregate of [•] authorized but unissued shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) or pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock in lieu thereof at an exercise price of $0.001 per share (the “Pre-Funded Warrant Shares”), and (ii) warrants (the “Warrants”) to purchase up to an aggregate of [•] shares of Common Stock (the “Warrant Shares”). The Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities”. The offering of the Securities pursuant hereto is referred to as the “Offering”.

Standard Contracts

Free NDA TemplateoneNDA-badgeFree SaaS TemplateoneSaaS-badge
•] Shares of Common Stock (or Pre-Funded Warrants to Purchase Shares of Common Stock in Lieu Thereof) Warrants to Purchase [•] Shares of Common Stock SYNLOGIC, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • September 27th, 2023 • Synlogic, Inc. • Pharmaceutical preparations • New York

Synlogic, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Chardan Capital Markets, LLC, as underwriter (“Chardan” or the “Underwriter”) (i) an aggregate of [•] authorized but unissued shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) or pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock in lieu thereof at an exercise price of $0.001 per share (the “Pre-Funded Warrant Shares”), and (ii) warrants (the “Warrants”) to purchase up to an aggregate of [•] shares of Common Stock (the “Warrant Shares”). The Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Warrants and the Warrant Shares are collectively referred to as the “Securities”. The offering of the Securities pursuant hereto is referred to as the “Offering”.

] Units Consisting of [ ] shares of Class A Common Stock and Warrants to Purchase [ ] shares of Class A Common Stock CELULARITY INC. UNDERWRITING AGREEMENT
Underwriting Agreement • May 11th, 2022 • Celularity Inc • Pharmaceutical preparations • New York

Celularity Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to BTIG, LLC, as representative (the “Representative”) of the several underwriters named on Schedule I hereto (each, an “Underwriter” and collectively, the “Underwriters”), (i) an aggregate of [ ] authorized but unissued shares (the “Firm Shares”) of Class A common stock, par value $0.0001 per share, of the Company (the “Common Stock”) and (ii) warrants (the “Firm Warrants”) to purchase up to an aggregate of [ ] shares of Common Stock (the “Firm Warrant Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth herein, up to an additional [ ] shares of Common Stock (the “Option Shares” and, together with the Firm Shares, the “Shares”) and/or Warrants (the “Option Warrants” and, together with the Firm Warrants, the “Warrants”) to purchase up to an additional [ ] shares of Common Stock (the “Option Warrant Sh

38,565,220 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 4,913,044 SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 32,608,698 SHARES OF COMMON STOCK SURGALIGN HOLDINGS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • February 15th, 2022 • Surgalign Holdings, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York

Surgalign Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to H.C. Wainwright & Co., LLC (the “Underwriter”) an aggregate of (i) 38,565,220 authorized but unissued shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to 4,913,044 shares of Common Stock, at an exercise price of $0.0001 per share, in the form attached hereto as Schedule V (the “Pre-Funded Warrants”) and (iii) common warrants to purchase up to 32,608,698 shares of Common Stock, at an exercise price of $0.60 per share, in the form attached hereto as Schedule VI (the “Firm Common Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The Company also proposes to sell to the Underwriter, at the option of the Underwriter, up to an additional 6,521,736, shares of Common Stock (the “Option Shares”) and/or

2,200,000 Shares Fresh Vine Wine, inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT
Underwriting Agreement • December 20th, 2021 • Fresh Vine Wine, Inc. • Beverages • New York
•] Common Units, Each Consisting of One Share of Common Stock and a Warrant to Purchase One Share of Common Stock [•] Pre-Funded Units, Each Consisting of a Pre-Funded Warrant to Purchase One Share of Common Stock and a Warrant to Purchase One Share...
Underwriting Agreement • September 26th, 2018 • Altimmune, Inc. • Pharmaceutical preparations • New York

Altimmune, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Roth Capital Partners, LLC (the “Underwriter”), (i) an aggregate of [•] authorized but unissued shares (the “Firm Shares”) of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”), (ii) pre-funded warrants (the “Firm Pre-Funded Warrants”) to purchase up to an aggregate of [•] shares of Common Stock at an exercise price of $0.01 per share (the “Firm Pre-Funded Warrant Shares”), and (iii) warrants (the “Firm Warrants”) to purchase up to an aggregate of [•] shares of Common Stock (the “Firm Warrant Shares”). The Firm Shares, the Firm Warrants, the Firm Pre-Funded Warrants, the Firm Pre-Funded Warrant Shares and the Firm Warrant Shares are collectively referred to as the “Firm Securities.” The Company also proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriter, (i) an aggregate of [•] a